147 related articles for article (PubMed ID: 21212092)
1. Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice.
Gault VA; Porter DW; Irwin N; Flatt PR
J Endocrinol; 2011 Mar; 208(3):265-71. PubMed ID: 21212092
[TBL] [Abstract][Full Text] [Related]
2. A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores.
Martin CM; Irwin N; Flatt PR; Gault VA
Biochim Biophys Acta; 2013 Jun; 1830(6):3407-13. PubMed ID: 23518200
[TBL] [Abstract][Full Text] [Related]
3. Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice.
Porter DW; Irwin N; Flatt PR; Hölscher C; Gault VA
Eur J Pharmacol; 2011 Jan; 650(2-3):688-93. PubMed ID: 21050845
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice.
Irwin N; Hunter K; Flatt PR
Peptides; 2007 Nov; 28(11):2192-8. PubMed ID: 17884253
[TBL] [Abstract][Full Text] [Related]
5. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
6. Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.
Irwin N; McClean PL; Hunter K; Flatt PR
Diabetes Obes Metab; 2009 Jun; 11(6):603-10. PubMed ID: 19515180
[TBL] [Abstract][Full Text] [Related]
7. An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice.
Hasib A; Ng MT; Gault VA; Khan D; Parthsarathy V; Flatt PR; Irwin N
Diabetologia; 2017 Mar; 60(3):541-552. PubMed ID: 28004148
[TBL] [Abstract][Full Text] [Related]
8. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
[TBL] [Abstract][Full Text] [Related]
9. Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice.
Irwin N; Hunter K; Flatt PR
Peptides; 2008 Jun; 29(6):1036-41. PubMed ID: 18291559
[TBL] [Abstract][Full Text] [Related]
10. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
McClean PL; Irwin N; Cassidy RS; Holst JJ; Gault VA; Flatt PR
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1746-55. PubMed ID: 17848629
[TBL] [Abstract][Full Text] [Related]
11. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
Irwin N; Hunter K; Montgomery IA; Flatt PR
Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of the biological activity of xenin-25 degradation fragment peptides.
Martin CM; Parthsarathy V; Pathak V; Gault VA; Flatt PR; Irwin N
J Endocrinol; 2014 May; 221(2):193-200. PubMed ID: 24520141
[TBL] [Abstract][Full Text] [Related]
13. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes.
Gault VA; Kerr BD; Irwin N; Flatt PR
Biochem Pharmacol; 2008 Jun; 75(12):2325-33. PubMed ID: 18455149
[TBL] [Abstract][Full Text] [Related]
14. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice.
Irwin N; Gault VA; Green BD; Greer B; McCluskey JT; Harriott P; O'Harte FP; Flatt PR
Biol Chem; 2004 Sep; 385(9):845-52. PubMed ID: 15493880
[TBL] [Abstract][Full Text] [Related]
15. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA
Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806
[TBL] [Abstract][Full Text] [Related]
16. Xenin-25[Lys13PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential.
Gault VA; Martin CM; Flatt PR; Parthsarathy V; Irwin N
Acta Diabetol; 2015 Jun; 52(3):461-71. PubMed ID: 25374384
[TBL] [Abstract][Full Text] [Related]
17. Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25.
Martin CM; Gault VA; McClean S; Flatt PR; Irwin N
Biochem Pharmacol; 2012 Aug; 84(3):312-9. PubMed ID: 22561048
[TBL] [Abstract][Full Text] [Related]
18. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.
Gault VA; McClean PL; Cassidy RS; Irwin N; Flatt PR
Diabetologia; 2007 Aug; 50(8):1752-62. PubMed ID: 17558485
[TBL] [Abstract][Full Text] [Related]
19. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice.
Lamont BJ; Drucker DJ
Diabetes; 2008 Jan; 57(1):190-8. PubMed ID: 17928394
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the long-term effects of gastric inhibitory polypeptide-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed mice.
Irwin N; Montgomery IA; Flatt PR
Br J Nutr; 2012 Jul; 108(1):46-56. PubMed ID: 22260799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
